DiaMedica Therapeutics Net Worth
DiaMedica Therapeutics Net Worth Breakdown | DMAC |
DiaMedica Therapeutics Net Worth Analysis
DiaMedica Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including DiaMedica Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of DiaMedica Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform DiaMedica Therapeutics' net worth analysis. One common approach is to calculate DiaMedica Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares DiaMedica Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing DiaMedica Therapeutics' net worth. This approach calculates the present value of DiaMedica Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of DiaMedica Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate DiaMedica Therapeutics' net worth. This involves comparing DiaMedica Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into DiaMedica Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if DiaMedica Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding DiaMedica Therapeutics' net worth research are outlined below:
| DiaMedica Therapeutics is way too risky over 90 days horizon | |
| DiaMedica Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (19.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| DiaMedica Therapeutics currently holds about 38.44 M in cash with (18.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
| DiaMedica Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 26.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Kuntz Richard of 9925 shares of DiaMedica Therapeutics at 5.34 subject to Rule 16b-3 |
DiaMedica Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in DiaMedica Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to DiaMedica Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
DiaMedica Therapeutics Target Price Consensus
DiaMedica target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. DiaMedica Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Strong Buy |
Most DiaMedica analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand DiaMedica stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of DiaMedica Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationDiaMedica Therapeutics Target Price Projection
DiaMedica Therapeutics' current and average target prices are 5.71 and 8.00, respectively. The current price of DiaMedica Therapeutics is the price at which DiaMedica Therapeutics is currently trading. On the other hand, DiaMedica Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
DiaMedica Therapeutics Market Quote on 18th of January 2025
Target Price
Analyst Consensus On DiaMedica Therapeutics Target Price
Know DiaMedica Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as DiaMedica Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading DiaMedica Therapeutics backward and forwards among themselves. DiaMedica Therapeutics' institutional investor refers to the entity that pools money to purchase DiaMedica Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-09-30 | 68.7 K | Qube Research & Technologies | 2024-09-30 | 52.1 K | Ronald Blue Trust, Inc. | 2024-09-30 | 44.2 K | Catalyst Financial Partners Llc | 2024-09-30 | 38.5 K | Millennium Management Llc | 2024-09-30 | 33.7 K | Jefferies Financial Group Inc | 2024-09-30 | 26 K | Citigroup Inc | 2024-09-30 | 22.1 K | Stonebridge Capital Advisors Llc | 2024-09-30 | 17.5 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 17 K | Cooperman Leon G | 2024-09-30 | 1.5 M | Vanguard Group Inc | 2024-09-30 | 1 M |
Follow DiaMedica Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 244.16 M.Market Cap |
|
Project DiaMedica Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.34) | |
| Return On Capital Employed | (0.48) | (0.50) | |
| Return On Assets | (0.32) | (0.34) | |
| Return On Equity | (0.44) | (0.46) |
When accessing DiaMedica Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures DiaMedica Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of DiaMedica Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of DiaMedica Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, DiaMedica Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of DiaMedica Therapeutics' management manipulating its earnings.
Evaluate DiaMedica Therapeutics' management efficiency
DiaMedica Therapeutics has return on total asset (ROA) of (0.2354) % which means that it has lost $0.2354 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3518) %, meaning that it created substantial loss on money invested by shareholders. DiaMedica Therapeutics' management efficiency ratios could be used to measure how well DiaMedica Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of January 18, 2025, Return On Tangible Assets is expected to decline to -0.34. In addition to that, Return On Capital Employed is expected to decline to -0.5. At present, DiaMedica Therapeutics' Non Current Assets Total are projected to decrease significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 64.8 M, whereas Non Currrent Assets Other are forecasted to decline to (0.94).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.41 | 1.05 | |
| Tangible Book Value Per Share | 1.41 | 1.48 | |
| Enterprise Value Over EBITDA | (4.12) | (4.32) | |
| Price Book Value Ratio | 2.08 | 1.98 | |
| Enterprise Value Multiple | (4.12) | (4.32) | |
| Price Fair Value | 2.08 | 1.98 | |
| Enterprise Value | 33.8 M | 29.7 M |
Evaluating the management effectiveness of DiaMedica Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The DiaMedica Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DiaMedica Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on DiaMedica Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases DiaMedica Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
DiaMedica Therapeutics Corporate Filings
F4 | 3rd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 7th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 18th of July 2024 Other Reports | ViewVerify |
DiaMedica Therapeutics Earnings Estimation Breakdown
The calculation of DiaMedica Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of DiaMedica Therapeutics is estimated to be -0.148125 with the future projection ranging from a low of -0.15 to a high of -0.145. Please be aware that this consensus of annual earnings estimates for DiaMedica Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.15 Lowest | Expected EPS | -0.14 Highest |
DiaMedica Therapeutics Earnings Projection Consensus
Suppose the current estimates of DiaMedica Therapeutics' value are higher than the current market price of the DiaMedica Therapeutics stock. In this case, investors may conclude that DiaMedica Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and DiaMedica Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 4 | 76.08% | -0.15 | -0.148125 | -0.56 |
DiaMedica Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of DiaMedica Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering DiaMedica Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of DiaMedica Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.DiaMedica Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as DiaMedica Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of DiaMedica Therapeutics should always be considered in relation to other companies to make a more educated investment decision.DiaMedica Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact DiaMedica Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-11 | 2024-09-30 | -0.15 | -0.15 | 0.0 | 0 | ||
2024-08-07 | 2024-06-30 | -0.16 | -0.13 | 0.03 | 18 | ||
2024-05-08 | 2024-03-31 | -0.16 | -0.14 | 0.02 | 12 | ||
2024-03-19 | 2023-12-31 | -0.14 | -0.14 | 0.0 | 0 | ||
2023-11-13 | 2023-09-30 | -0.13 | -0.12 | 0.01 | 7 | ||
2023-08-14 | 2023-06-30 | -0.18 | -0.16 | 0.02 | 11 | ||
2023-05-15 | 2023-03-31 | -0.16 | -0.2 | -0.04 | 25 | ||
2023-03-28 | 2022-12-31 | -0.14 | -0.14 | 0.0 | 0 | ||
2022-11-09 | 2022-09-30 | -0.15 | -0.12 | 0.03 | 20 | ||
2022-08-10 | 2022-06-30 | -0.18 | -0.13 | 0.05 | 27 | ||
2022-05-04 | 2022-03-31 | -0.21 | -0.13 | 0.08 | 38 | ||
2022-03-14 | 2021-12-31 | -0.18 | -0.1 | 0.08 | 44 | ||
2021-11-10 | 2021-09-30 | -0.23 | -0.18 | 0.05 | 21 | ||
2021-08-11 | 2021-06-30 | -0.21 | -0.17 | 0.04 | 19 | ||
2021-05-05 | 2021-03-31 | -0.21 | -0.19 | 0.02 | 9 | ||
2021-03-10 | 2020-12-31 | -0.17 | -0.23 | -0.06 | 35 | ||
2020-11-04 | 2020-09-30 | -0.15 | -0.19 | -0.04 | 26 | ||
2020-08-11 | 2020-06-30 | -0.15 | -0.17 | -0.02 | 13 | ||
2020-05-13 | 2020-03-31 | -0.28 | -0.19 | 0.09 | 32 | ||
2020-03-23 | 2019-12-31 | -0.25 | -0.21 | 0.04 | 16 | ||
2019-11-13 | 2019-09-30 | -0.21 | -0.2 | 0.01 | 4 | ||
2019-08-13 | 2019-06-30 | -0.26 | -0.21 | 0.05 | 19 | ||
2019-05-13 | 2019-03-31 | -0.2 | -0.27 | -0.07 | 35 | ||
2019-03-19 | 2018-12-31 | -0.2 | -0.23 | -0.03 | 15 | ||
2014-11-28 | 2014-09-30 | -0.2 | -0.4 | -0.2 | 100 | ||
2014-08-28 | 2014-06-30 | -0.6 | -0.4 | 0.2 | 33 | ||
2014-05-29 | 2014-03-31 | -0.6 | -0.8 | -0.2 | 33 |
DiaMedica Therapeutics Corporate Management
| MS MD | Independent Consultant | Profile | |
| Scott CA | CFO Sec | Profile | |
| Edward Calamai | Consulting Manufacturing | Profile | |
| Ambarish Shah | Chief Officer | Profile | |
| Lorianne MD | Chief Officer | Profile | |
| Julie CCRP | Senior Operations | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.